Lazard Asset Management’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $99.5K | Buy |
1,327
+620
| +88% | +$39.8K | ﹤0.01% | 1756 |
|
|
2026
Q1 | $39.8K | Sell |
707
-2,952
| -81% | -$192K | ﹤0.01% | 1791 |
|
|
2025
Q4 | $293K | Buy |
+3,659
| New | +$246K | ﹤0.01% | 1540 |
|
|
2025
Q3 | – | Sell |
-707
| Closed | -$52K | – | 2027 |
|
|
2025
Q2 | $52K | Sell |
707
-2,454
| -78% | -$162K | ﹤0.01% | 2005 |
|
|
2025
Q1 | $200K | Sell |
3,161
-18,775
| -86% | -$1.28M | ﹤0.01% | 1625 |
|
|
2024
Q4 | $1.71M | Buy |
21,936
+6,170
| +39% | +$496K | ﹤0.01% | 938 |
|
|
2024
Q3 | $1.27M | Buy |
15,766
+7,309
| +86% | +$590K | ﹤0.01% | 1009 |
|
|
2024
Q2 | $698K | Sell |
8,457
-1,911
| -18% | -$168K | ﹤0.01% | 1076 |
|
|
2024
Q1 | $884K | Sell |
10,368
-26,088
| -72% | -$2.05M | ﹤0.01% | 946 |
|
|
2023
Q4 | $3.12M | Sell |
36,456
-2,082
| -5% | -$180K | ﹤0.01% | 777 |
|
|
2023
Q3 | $3.45M | Buy |
38,538
+20,550
| +114% | +$1.83M | ﹤0.01% | 769 |
|
|
2023
Q2 | $1.53M | Sell |
17,988
-25,441
| -59% | -$2.15M | ﹤0.01% | 926 |
|
|
2023
Q1 | $3.59M | Buy |
43,429
+1,658
| +4% | +$134K | ﹤0.01% | 791 |
|
|
2022
Q4 | $3.29M | Sell |
41,771
-2,173
| -5% | -$175K | ﹤0.01% | 805 |
|
|
2022
Q3 | $3.25M | Buy |
+43,944
| New | +$3.16M | ﹤0.01% | 791 |
|
|
2022
Q1 | – | Sell |
-42,306
| Closed | -$2.24M | – | 2403 |
|
|
2021
Q4 | $2.24M | Buy |
42,306
+42,259
| +89,913% | +$2.57M | ﹤0.01% | 917 |
|
|
2021
Q3 | $3K | Hold |
47
| – | – | ﹤0.01% | 2110 |
|
|
2021
Q2 | $3K | Sell |
47
-33,598
| -100% | -$2.38M | ﹤0.01% | 1919 |
|
|
2021
Q1 | $3.73M | Buy |
33,645
+33,222
| +7,854% | +$4.11M | ﹤0.01% | 704 |
|
|
2020
Q4 | $50K | Hold |
423
| – | – | ﹤0.01% | 1389 |
|
|
2020
Q3 | $36K | Buy |
423
+187
| +79% | +$16.3K | ﹤0.01% | 1284 |
|
|
2020
Q2 | $21K | Sell |
236
-470
| -67% | -$47.5K | ﹤0.01% | 1429 |
|
|
2020
Q1 | $70K | Buy |
+706
| New | +$76.6K | ﹤0.01% | 1079 |
|
|
2019
Q1 | – | Sell |
-3,623
| Closed | -$362K | – | 1167 |
|
|
2018
Q4 | $362K | Buy |
3,623
+3,079
| +566% | +$323K | ﹤0.01% | 815 |
|
|
2018
Q3 | $62K | Sell |
544
-3,809
| -88% | -$394K | ﹤0.01% | 943 |
|
|
2018
Q2 | $390K | Sell |
4,353
-3,140
| -42% | -$265K | ﹤0.01% | 798 |
|
|
2018
Q1 | $548K | Buy |
7,493
+2,772
| +59% | +$190K | ﹤0.01% | 767 |
|
|
2017
Q4 | $274K | Buy |
+4,721
| New | +$249K | ﹤0.01% | 849 |
|
|
2014
Q1 | – | Sell |
-191,256
| Closed | -$8.06M | – | 1033 |
|
|
2013
Q4 | $8.06M | Sell |
191,256
-55,869
| -23% | -$2.3M | 0.02% | 415 |
|
|
2013
Q3 | $9.86M | Buy |
247,125
+2,862
| +1% | +$120K | 0.02% | 359 |
|
|
2013
Q2 | $10.1M | Buy |
+244,263
| New | +$9.89M | 0.02% | 361 |
|
Other funds holding HAE
AI
Lazard Asset Management's HAE Position: Q2 2026 in Review
Lazard Asset Management increased its Haemonetics (HAE) stake by 88% in Q2 2026, buying an estimated $39.8K and bringing the position to 1,327 shares worth $99.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1756.
Lazard Asset Management first reported a position in HAE in Q2 2013 and has held it in 31 quarters since. The position peaked at $10.1M in Q2 2013. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Lazard Asset Management held 1,327 shares of Haemonetics worth $99.5K as of Q2 2026.
- Lazard Asset Management bought 620 Haemonetics shares in Q2 2026, an estimated $39.8K.
- Haemonetics made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1756 holding.
- Lazard Asset Management first reported a position in Haemonetics in Q2 2013 and has held it in 31 quarters since.
- Lazard Asset Management's Haemonetics position peaked at $10.1M in Q2 2013.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.